Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alex Azar And The Return Of Republican-Style Price Negotiation

Executive Summary

The nomination of a former drug industry executive to run HHS is obviously good news for the biopharma sector, but it does not mean that HHS will do nothing about drug prices. On the contrary, it may make some high-profile action against pricing outliers all but inevitable.

You may also be interested in...



Trump Expecting Rx Price Reduction Announcements In Two Weeks

Look for Administration to take credit for any positive pricing news as President says several firms will 'announce voluntary massive drops in prices.'

The Spectacle Of Trump: Tweets, Insults And A Year Pharma Won't Forget

From "getting away with murder" to "rip-off drug prices," pharma had its share of face-offs with President Trump in 2017. In the end, industry appears to have fared well under the pro-business leader, with industry insider Alex Azar now heading HHS and corporate tax reform a new year treat for industry.

HHS Nominee Azar And The Taint Of Industry

During the first step of the confirmation process, HHS Secretary nominee Alex Azar did a good job of framing his industry background as useful experience for tackling drug prices. But wouldn’t it be nice if everyone agreed that 10 years as Lilly was something to be proud of?

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS122018

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel